Phase 2 UNITY-NHL Study Regarding Umbralisib episode artwork

EPISODE · Apr 15, 2021 · 2 MIN

Phase 2 UNITY-NHL Study Regarding Umbralisib

from Rare Disease Discussions · host CheckRare Editors

Owen A. O’Connor, Chief Scientific Officer at TG Therapeutics, describes the phase 2 UNITY-NHL study, the results of which led to the FDA’s approval of umbralisib.Rare Discussions is produced by CheckRare, the leading multimedia platform dedicated to advancing education, awareness, and innovation across the rare disease community.Explore additional physician interviews, podcasts, CME activities, and rare disease resources at CheckRare.com.Subscribe to the CheckRare Podcast Network for expert conversations, weekly news, accredited education, and the latest advances across the rare disease community.Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.

Episode metadata supplied by the publisher feed · Published Apr 15, 2021

Embed this episode

NOW PLAYING

Phase 2 UNITY-NHL Study Regarding Umbralisib

0:00 2:32

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Rare Disease Discussions?

This episode is 2 minutes long.

When was this Rare Disease Discussions episode published?

This episode was published on April 15, 2021.

Can I download this Rare Disease Discussions episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!